Literature DB >> 28073001

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.

Jin-Sung Park, Il-Kug Kim, Sangyeul Han, Intae Park, Chan Kim, Jeomil Bae, Seung Ja Oh, Seungjoo Lee, Jeong Hoon Kim, Dong-Cheol Woo, Yulong He, Hellmut G Augustin, Injune Kim, Doheon Lee, Gou Young Koh.   

Abstract

Entities:  

Year:  2017        PMID： 28073001     DOI： 10.1016/j.ccell.2016.12.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  13 in total

Review 1.  Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context.

Authors:  Mannon Geindreau; Mélanie Bruchard; Frédérique Vegran
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

2.  Resveratrol Promotes Tumor Microvessel Growth via Endoglin and Extracellular Signal-Regulated Kinase Signaling Pathway and Enhances the Anticancer Efficacy of Gemcitabine against Lung Cancer.

Authors:  San-Hai Qin; Andy T Y Lau; Zhan-Ling Liang; Heng Wee Tan; Yan-Chen Ji; Qiu-Hua Zhong; Xiao-Yun Zhao; Yan-Ming Xu
Journal:  Cancers (Basel)       Date:  2020-04-15       Impact factor: 6.639

3.  IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.

Authors:  Lei Zhang; Liqun He; Roberta Lugano; Kenney Roodakker; Michael Bergqvist; Anja Smits; Anna Dimberg
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 13.029

4.  Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy.

Authors:  Wenguang Wang; Yuhao Cheng; Peng Yu; Haoran Wang; Yue Zhang; Haiheng Xu; Qingsong Ye; Ahu Yuan; Yiqiao Hu; Jinhui Wu
Journal:  Nat Commun       Date:  2019-04-05       Impact factor: 14.919

5.  Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy.

Authors:  Iris Uribesalgo; David Hoffmann; Yin Zhang; Anoop Kavirayani; Jelena Lazovic; Judit Berta; Maria Novatchkova; Tsung-Pin Pai; Reiner A Wimmer; Viktória László; Daniel Schramek; Rezaul Karim; Luigi Tortola; Sumit Deswal; Lisa Haas; Johannes Zuber; Miklós Szűcs; Keiji Kuba; Balazs Dome; Yihai Cao; Bernhard J Haubner; Josef M Penninger
Journal:  EMBO Mol Med       Date:  2019-06-24       Impact factor: 12.137

Review 6.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

7.  Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.

Authors:  Chunbo Zhao; Qian Zhang; Wenbo Qiao
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner.

Authors:  Shengming Deng; Guoxi Zhang; Jiajie Kuai; Peng Fan; Xuexiang Wang; Pei Zhou; Dan Yang; Xichen Zheng; Xiaomei Liu; Qunli Wu; Yuhui Huang
Journal:  J Exp Clin Cancer Res       Date:  2018-10-29

Review 9.  The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.

Authors:  Christopher P Wilding; Mark L Elms; Ian Judson; Aik-Choon Tan; Robin L Jones; Paul H Huang
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-13       Impact factor: 4.512

10.  Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.

Authors:  Xinran Ma; Ling Li; Lei Zhang; Xiaorui Fu; Xin Li; Xinhua Wang; Jingjing Wu; Zhenchang Sun; Xudong Zhang; Xiaoyan Feng; Yu Chang; Zhiyuan Zhou; Feifei Nan; Jieming Zhang; Zhaoming Li; Mingzhi Zhang
Journal:  Drug Des Devel Ther       Date:  2020-01-22       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.